245 related articles for article (PubMed ID: 26755074)
21. EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
Eskilsson E; Rosland GV; Talasila KM; Knappskog S; Keunen O; Sottoriva A; Foerster S; Solecki G; Taxt T; Jirik R; Fritah S; Harter PN; Välk K; Al Hossain J; Joseph JV; Jahedi R; Saed HS; Piccirillo SG; Spiteri I; Leiss L; Euskirchen P; Graziani G; Daubon T; Lund-Johansen M; Enger PØ; Winkler F; Ritter CA; Niclou SP; Watts C; Bjerkvig R; Miletic H
Neuro Oncol; 2016 Dec; 18(12):1644-1655. PubMed ID: 27286795
[TBL] [Abstract][Full Text] [Related]
22. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.
Messaoudi K; Clavreul A; Lagarce F
Drug Discov Today; 2015 Jul; 20(7):899-905. PubMed ID: 25744176
[TBL] [Abstract][Full Text] [Related]
23. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
[TBL] [Abstract][Full Text] [Related]
24. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
25. Sprouty2 Drives Drug Resistance and Proliferation in Glioblastoma.
Walsh AM; Kapoor GS; Buonato JM; Mathew LK; Bi Y; Davuluri RV; Martinez-Lage M; Simon MC; O'Rourke DM; Lazzara MJ
Mol Cancer Res; 2015 Aug; 13(8):1227-37. PubMed ID: 25934697
[TBL] [Abstract][Full Text] [Related]
26. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
Lv S; Teugels E; Sadones J; De Brakeleer S; Duerinck J; Du Four S; Michotte A; De Grève J; Neyns B
Int J Oncol; 2012 Sep; 41(3):1029-35. PubMed ID: 22752145
[TBL] [Abstract][Full Text] [Related]
27. Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms.
Klingler S; Guo B; Yao J; Yan H; Zhang L; Vaseva AV; Chen S; Canoll P; Horner JW; Wang YA; Paik JH; Ying H; Zheng H
Cancer Res; 2015 May; 75(10):2109-19. PubMed ID: 25808866
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma.
Azuaje F; Tiemann K; Niclou SP
Cell Commun Signal; 2015 Mar; 13():23. PubMed ID: 25885672
[TBL] [Abstract][Full Text] [Related]
29. β-Elemene enhances the efficacy of gefitinib on glioblastoma multiforme cells through the inhibition of the EGFR signaling pathway.
Mu L; Wang T; Chen Y; Tang X; Yuan Y; Zhao Y
Int J Oncol; 2016 Oct; 49(4):1427-36. PubMed ID: 27498706
[TBL] [Abstract][Full Text] [Related]
30. [Targeting EGFRvIII for treatment of glioblastoma: From molecular mechanisms to clinical strategies].
Chen S; Li X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Nov; 44(11):1281-1286. PubMed ID: 31919324
[TBL] [Abstract][Full Text] [Related]
31. Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
Sooman L; Ekman S; Andersson C; Kultima HG; Isaksson A; Johansson F; Bergqvist M; Blomquist E; Lennartsson J; Gullbo J
Cancer Chemother Pharmacol; 2013 Aug; 72(2):329-40. PubMed ID: 23736154
[TBL] [Abstract][Full Text] [Related]
32. SHP-2-dependent mitogen-activated protein kinase activation regulates EGFRvIII but not wild-type epidermal growth factor receptor phosphorylation and glioblastoma cell survival.
Zhan Y; O'Rourke DM
Cancer Res; 2004 Nov; 64(22):8292-8. PubMed ID: 15548697
[TBL] [Abstract][Full Text] [Related]
33. The EGFRvIII variant in glioblastoma multiforme.
Gan HK; Kaye AH; Luwor RB
J Clin Neurosci; 2009 Jun; 16(6):748-54. PubMed ID: 19324552
[TBL] [Abstract][Full Text] [Related]
34. HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.
Wang Z; Hu P; Tang F; Lian H; Chen X; Zhang Y; He X; Liu W; Xie C
Cancer Lett; 2016 Aug; 379(1):134-42. PubMed ID: 27267806
[TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
Mamot C; Drummond DC; Noble CO; Kallab V; Guo Z; Hong K; Kirpotin DB; Park JW
Cancer Res; 2005 Dec; 65(24):11631-8. PubMed ID: 16357174
[TBL] [Abstract][Full Text] [Related]
36. Alteration of major vault protein in human glioblastoma and its relation with EGFR and PTEN status.
Navarro L; Gil-Benso R; Megías J; Muñoz-Hidalgo L; San-Miguel T; Callaghan RC; González-Darder JM; López-Ginés C; Cerdá-Nicolás MJ
Neuroscience; 2015 Jun; 297():243-51. PubMed ID: 25869624
[TBL] [Abstract][Full Text] [Related]
37. Herstatin, an autoinhibitor of the epidermal growth factor receptor family, blocks the intracranial growth of glioblastoma.
Staverosky JA; Muldoon LL; Guo S; Evans AJ; Neuwelt EA; Clinton GM
Clin Cancer Res; 2005 Jan; 11(1):335-40. PubMed ID: 15671564
[TBL] [Abstract][Full Text] [Related]
38. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
Mellinghoff IK; Wang MY; Vivanco I; Haas-Kogan DA; Zhu S; Dia EQ; Lu KV; Yoshimoto K; Huang JH; Chute DJ; Riggs BL; Horvath S; Liau LM; Cavenee WK; Rao PN; Beroukhim R; Peck TC; Lee JC; Sellers WR; Stokoe D; Prados M; Cloughesy TF; Sawyers CL; Mischel PS
N Engl J Med; 2005 Nov; 353(19):2012-24. PubMed ID: 16282176
[TBL] [Abstract][Full Text] [Related]
39. Transactivation of the epidermal growth factor receptor by formylpeptide receptor exacerbates the malignant behavior of human glioblastoma cells.
Huang J; Hu J; Bian X; Chen K; Gong W; Dunlop NM; Howard OM; Wang JM
Cancer Res; 2007 Jun; 67(12):5906-13. PubMed ID: 17575160
[TBL] [Abstract][Full Text] [Related]
40. Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.
Gan HK; van den Bent M; Lassman AB; Reardon DA; Scott AM
Nat Rev Clin Oncol; 2017 Nov; 14(11):695-707. PubMed ID: 28675164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]